Global expansion MERIT CRO has recently expanded with the establishment of MERIT CRO AUSTRALIA, indicating a growth trajectory and potential cross-border clinical trial support opportunities in Oceania and surrounding regions.

Preclinical to clinical Post-acquisition of OSOD, MERIT now offers preclinical research services alongside endpoints, presenting a cross-stage integrated service proposition that can upsell from preclinical studies to clinical endpoint services.

Endpoint leadership With a proven track record providing endpoint expertise to a majority of the top global pharma companies and a history of rapid growth, MERIT positions as a trusted partner for large-portfolio or high-stakes trials requiring robust endpoint solutions.

Leadership depth Recent COO appointment signals operational scaling and focus on performance, process optimization, and global delivery capabilities that can support larger trials and extended service lines.

Financial performance Strong revenue range combined with listed growth credentials suggests capacity for expanded capacity, co-investment opportunities, and possibility to partner on expanded trial programs or new therapeutic areas.